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ORIGINAL ARTICLE
Electroconvulsive therapy in geriatric patients: A literature review and program
report from Virginia Commonwealth University, Richmond, Virginia, USA
Andrew D. Snyder, Vasu Venkatachalam, Ananda K. Pandurangi
Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA

ABSTRACT
Electroconvulsive therapy (ECT) is an effective therapeutic intervention in the elderly patients with major depression, especially
those with psychosis, suicidality, catatonia, nutritional compromise, and resistance to medications. Response rates can be as
high as 80%. We present an extensive review of the relevant literature, provide a description of the ECT program at Virginia
Commonwealth University in Richmond, Virginia, USA, and present results of our experience with ECT in fifty elderly patients.
The treatments were safe, well tolerated, and produced high response rates, variably between 68% and 84%. Patients in the
long‑term maintenance ECT program continue to show sustained benefits from ECT.
Key words: Electroconvulsive therapy, geriatric, program

INTRODUCTION
It is by now well documented that more than a third
of patients with major depressive disorder (MDD)
fail to respond to recommended pharmacologic and
psychotherapeutic treatments.[1] Such patients may be
appropriately termed as having “treatment resistant
or refractory depression” (TRD). This condition
necessitates the use of a more invasive therapy such as
electroconvulsive therapy (ECT). ECT also produces a
more rapid response than medications and psychotherapy,
making ECT, especially useful in suicidal patients and
nutritionally compromised patients where rapid response
is essential.[2‑4] ECT may be superior to medications
in more challenging cases where patients suffer from
depression with psychotic features or catatonic features.[5]
Finally, ECT is effective in psychotic and manic disorders
and should be considered when first‑ and second‑line
therapies for these conditions have not been effective or
have only produced a partial response.[6] All of the above
indications apply just as much in the geriatric population
as in adults.

LITERATURE REVIEW
A PubMed and Google Scholar literature search was
conducted with the terms “ECT,” “electroconvulsive
therapy” and “geriatric or elderly after geriatric” for the
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time period between 2000 and 2017; the search yielded
more than seventy unique studies which were reviewed.

Efficacy

ECT has been cited as effective in as many as 70%–80%
of geriatric patients with MDD, independent of age, or any
preexisting cognitive impairment.[7‑15] Existing evidence
suggests that objective signs of response are supported by
subjective report[16] and may be observed more quickly
in the course of treatment.[17] One multisite study of
253 patients of varying ages even reported that increasing
age positively influenced response to treatment;[18] this
possibility is reinforced by a relatively lower rate of
rehospitalization in geriatric patients treated with ECT
with respect to the nongeriatric population.[19] Although
controversial, factors including temporal lobe atrophy (but
not global atrophy),[20] cardiac vagal modulation,[21,22] and
subcortical gray matter hyperintensity lesions[23,24] have
been reported as biological factors potentially limiting
efficacy and perhaps increasing mortality; a number of
potential structural differences such as smaller temporal
cortex and hippocampal volume have been identified as
predictive of greater treatment response.[25,26] In addition,
longer postictal recovery times have been associated
with quicker response to therapy.[27] One larger study of
239 geriatric patients indicated a lack of social support,
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poor self‑reported health rating, as well as the use of
antipsychotic or antidepressant medications as predictors
of longer time to remission whereas use of ECT in the past
year was associated with shorter time to remission.[28] One
possible mechanism proposed for the efficacy of ECT in
geriatric patients was a relative increase in frontal lobe
white matter identified by diffusion tensor imaging in
eight depressed geriatric patients, ameliorating suspected
problems in white matter integrity.[29]
Both right unilateral (RUL) and bifrontal (BF) lead
placements have demonstrated strong efficacy in treating
depression in the elderly.[30,31] High‑dose RUL ECT was
demonstrated in one study to be more efficacious than
bilateral ECT in a group of elderly patients after they had
failed to improve on moderate dose RUL ECT.[31] To help in
deciding whether to continue RUL or switch to BL therapy,
one study proposed using electroencephalogram (EEG)
indices as a guide for determining likelihood of benefit
when RUL ECT appeared inadequate in an elderly
cohort.[32] In the absence of definitive evidence, in our
program, ECT is always started with RUL placement for
MDD without psychosis – see program description below
for more details on this.
Combination pharmacologic and ECT were shown to be
more rapidly efficacious than monotherapy[33,34] in treating
unipolar depression in the elderly with greater survival time
and no apparent loss of tolerability.[35] This trend was also
observed with combination therapy of psychotic depression
in the maintenance phase.[36] Although evidence is relatively
more sparse, ECT is reported to be effective in treating bipolar
depression,[10] agitation in dementia patients,[37‑39] bipolar
mania in dementia patients,[40‑42] catatonic schizophrenia,[43,44]
and depression in multisystem atrophy.[45] Finally, due to
significant rates of relapse in treating depression, maintenance
combination therapy is recommended.[46] Maintenance ECT
has been demonstrated to be effective in limiting relapse in
patients with catatonic schizophrenia[47] as well as dementia
with agitation and manic symptoms.[43]

Safety

Overall, ECT has been demonstrated to be relatively safe
and well tolerated in the geriatric population,[9,11,33] and the
incidence of adverse effects may be independent of age.[48]
One study of 52 geriatric patients treated with ECT found
that about twenty patients (38%) reported adverse effects
including memory loss, confusion, and hypertension,
suggesting a need for careful consideration of such factors
when recommending ECT for geriatric patients.[8] Overall,
cognitive deficits were the most commonly reported side
effect of ECT ranging from 6% to 40% in nondemented
elderly. These side effects were reported as transient or
reversible,[10,18,49] and it has also been reported that cognitive
function can be overall unaffected or may actually improve
with ECT treatment over the longer term.[50‑52] No specific
and reliable data are available on the prevalence of postictal
delirious state in the elderly; in our own experience,
this does happen rarely and quickly reverses. Ensuring
hydration and normal electrolytes as well as avoiding
long seizures or excessive sedating medication might help
avoid this. RUL placement of electrodes has demonstrated
116

fewer cognitive side effects.[53] Unlike in adults, no data are
available on the relation between individual stimulation
parameters such as electrical charge, frequency, pulse
width, and energy delivered and cognitive side effects in
the elderly. The same lack of data is also true for anesthetic
and paralyzing agents. Neuropsychological assessment has
shown both retrograde and anterograde deficits with the
most common being delayed verbal anterograde memory.[50]
More serious or life‑threatening adverse effects included
an increased rate of falls[54] as well as increased incidence
of bigeminy and trigeminy as well as supraventricular
tachycardia[55,56] associated with treatment. Despite these
potential risks, administration of ECT to patients with
intracardiac defibrillators was determined to be safe
by a number of studies.[51] Generally speaking, serious
medical conditions become relative contraindications to
ECT which can be overcome by the involvement of the
appropriate consulting professionals.[57,58] In comparison
with other modalities of treatment, one review pointed
to prior results which indicated a relatively lower rate
of side effects associated with ECT in comparison to
pharmacotherapy in patients >75 years of age.[59] No
difference in brain perfusion was detected between the two
treatment modalities;[60] however, it has been noted that
lower average pre‑ECT hemispheric cerebral blood flow
and EEG mean signal has been associated with increased
risk of developing dementia.[61]

Accessibility

Due to the medically intensive nature of the ECT procedure
and longer periods of postprocedure observation, cost,
and thus accessibility of treatment is a concern. Indeed,
one European postal survey demonstrated that access was
most frequently limited by cost.[62] One Canadian review of
healthcare data of 12 million citizens indicated that ECT was
more commonly prescribed in elderly patients with respect
to other adults and that it remains a commonly prescribed
treatment.[63] Perhaps paradoxically, reservations about
utilization of ECT held by clinicians may also limit access
as suggested by one study of geriatric psychiatrists in the
Netherlands.[64] Decision‑making capacity does not appear
to be a barrier to access overall, and psychoeducation
is effective in further improving capacity;[65] however,
there exists a threshold in cognitive functioning past
which psychoeducation is ineffective in further improving
decision‑making capacity.[66] The authors of the study
opined that this limitation may be due to a ceiling effect
and/or psychosis. Fear and social stigma associated with the
treatment are significant barriers as well as limited access
to psychiatric consultants and appropriately equipped
facilities.[67] Animal‑assisted therapy may have a useful role
in defraying the preprocedural anxiety and fear associated
with ECT and improve access and adherence.[68] In this
study conducted in our program, 15 min of interaction
with a therapy dog while awaiting the ECT procedure
significantly reduced fear and anxiety.
Although not directly relevant to this report, it is
appropriate to briefly note that transcranial magnetic
stimulation (TMS) is also a brain stimulation therapy
applicable to TRD in the geriatric population but is more
controversial from an efficacy standpoint; some studies
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have suggested unambiguous efficacy[69,70] whereas others
indicate an inverse relationship between age and efficacy,
suggesting relatively lesser utility in the elderly.[71,72]

PROGRAM DESCRIPTION
The Department of Psychiatry at Virginia Commonwealth
University Health System (VCUHS) provides a Brain
Stimulation Therapy Program which includes clinical,
educational, and research components. The clinical service
is located within the medical psychiatry inpatient division
and includes a dedicated ECT suite and four beds. Other
components of this program not described here include
TMS therapy located in a dedicated TMS therapy suite,
vagal nerve stimulation therapy, ketamine infusion for
depression in collaboration with anesthesiology, and a
research program of deep brain stimulation for depression
in collaboration with the Department of Neurosurgery.
Patients referred to the ECT program are from the entire
Commonwealth of Virginia spanning approximately
200 miles in width and 430 miles in length and a
population of 8.5 million. Although the program at VCUHS
is the largest in the Commonwealth, there are seven other
programs offering ECT. In recent years, our program has
been evaluating approximately 225 patients annually
for ECT, 75% of which are outpatients. Typical inpatient
referrals are for those with catatonia, psychotic depression,
suicidality, and severe mania. About 175 of these eventually
receive ECT. There are also approximately 25 patients
receiving maintenance ECT annually. Between 20% and
25% of all ECT patients are above the age of 65 years. Both
inpatients and outpatients receive a standard evaluation
focused on ECT by a senior consulting psychiatrist (AKP).
The ECT evaluation, in addition to standard psychiatric
elements, focuses on verifying the primary diagnosis,
prior treatment history both during the past and present
episodes, specific factors that favor ECT including
weight loss, electrolyte imbalance, suicidality, mood
congruent delusions, and catatonia. Factors increasing
risk are also carefully gathered and reviewed. For example,
cardiomyopathy, low ejection fraction, pacemakers,
bradycardia, risk of arrhythmia, and risk of aspiration
and apnea. Depression is rated on the Montgomery–Asberg
Depression Rating Scale (MADRS) on all patients.
Capacity to consent, surrogate consent in assenters without
full capacity, and court permission for involuntary ECT
are reviewed and implemented as appropriate. Logistics,
schedule, transport, and supervision are especially reviewed
for outpatients. All patients and significant others are shown an
ECT video as well as provided with an ECT brochure, sample
consent form, and outpatient safety instructions. Patients
and family are encouraged to read the material and call back
with any questions before the first treatment. Appropriate
medical clearances are obtained as needed such as from
a cardiologist or surgeon in patients who have undergone
recent surgery. The minimum laboratory tests required
before first ECT include complete hematology (complete
blood count), comprehensive metabolic panel, and a 12‑lead
electrocardiogram (EKG). Additional tests are ordered on as
needed basis. Outpatients and a family member receive a

one‑page outpatient ECT instruction sheet specifying taking
nil per os after 12 midnight the night before ECT; taking
morning medications with small sips of clear water; and
seeking assistance of a responsible adult for transportation
to and from the treatment session. Patients coming from
other hospitals and nursing homes are expected to bring
their complete medication list. Anticonvulsant medications,
lithium, tricyclics, seizure‑enhancing medications such
as clozapine and bupropion are reviewed for doses and
regimens, and individualized instructions are provided on
whether to hold the medication, reduce dose, or continue
the medication. More caution is exercised before the first
four treatments, and subsequent changes are made based
on patient response and safety events.
The procedure staff consists of a faculty psychiatrist/
interventionist, two registered psychiatry nurses one of
whom is in the treatment room, a psychiatry resident, a
faculty anesthesiologist, and a certified registered nurse
anesthetist (CRNA). Several other trainees may be present
in the treatment room such as medical or nursing students.
Significant others and family member are allowed to stay
with patient until they are sedated. Pre‑ECT evaluation is
conducted before every treatment and includes assessment
of current complaints, update of psychiatric and medical
history since initial evaluation, review of systems, physical
examination, review of medications, and laboratory blood
draws. The patient is examined separately by the resident or
nurse practitioner, attending psychiatrist and anesthesiologist.
Once in the treatment suite, the patient is connected
to various safety monitors including EEG, EKG,
electromyogram (one limb), oximetry, CO2, tidal volumes,
and blood pressure and heart rate. A time‑out is called
and documented to verify patient identity, procedure,
lead placement, and electrical charge. Typically, sedation
is achieved with 1 mg/kg of methohexital and muscle
paralysis with 1 mg/kg of succinylcholine/kg. Alternative
sedatives include etomidate and propofol. Alternative
muscle relaxants are nondepolarizing agents such as
rocuronium and mivacurium. Prophylactic medications
are administered as needed and are jointly decided by the
anesthesiologist and psychiatrist. Commonly administered
medications include labetalol for blood pressure control,
ondansetron for nausea, ketorolac for pain, and ranitidine
to reduce gastric acidity. Atropine or glycopyrrolate is not
administered unless there is a specific indication such
as history of extensive secretion in a prior treatment.
Oxygenation is provided by the CRNA. Vital signs are
continuously monitored including heart rate, blood
pressure, heart rhythm, oxygen saturation, CO2, muscle
activity in the left foot, and EEG. Upon obtaining sufficient
sedation and muscle paralysis, electrical stimulation is
administered through a Somatics, LLC, Thymatron IV
machine. Electrode placement is determined initially by
the psychiatric consultant who evaluates the patient, then
on an ongoing basis by the psychiatrist/interventionist.
Patients with MDD are typically started with RUL and
brief pulse width of 0.5 ms and a charge based on the
half‑age method. If necessary, the charge is titrated up
at each treatment, to obtain a seizure of at least 25 s on
the EEG. After 4 treatments, patients are reevaluated
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Figure 1: Electroconvulsive therapy procedure expandable e-form

Figure 1: Contd...

ECT history, procedure and progress note ‑ VCUHS

ECT history, procedure and progress note ‑ VCUHS

Name, DOB, MRN
Treatment number (index/maintenance)
Most recent consent date
Diagnoses (psychiatric)
Diagnoses (medical)
Rating scales (optional)
Befor 1st ECT: Complete the applicable scale of psychiatric
symptoms (MADRS or GDS or YMRS) + MMSE and CGS
Every 4th ECT or every 4 weeks and after the last ECT: Complete the
applicable scales and CGS/CGI
Insert rating scale here: Click on rubber stamp to insert appropriate
rating scale
Psychiatric status
Note brief history, any changes since last ECT in symptoms,
stressors, life situation (obtained from patient, escort, and record)
Medical status
At 1st treatment, note status pre‑ECT; then any changes since last
treatment in symptoms, function, and new problems (ROS)
Focused physical exam
Vital signs
HEENT
Cardiac
Resp
Abdomen
CNS
Pain
Pain score (0‑10)
Labs, EKG, radiology and other tests: Note baseline at 1st ECT; then
any changes since last ECT
Current medications: Verified with patient, family or escort and most
recent records
Psychotropics (include dose)
Nonpsychotropics (list)
ECT treatment record ‑ VCU health system
Today’s treatment date
Today’s treatment time
Attending psychiatrist
Assistants
Description of procedure
Today’s treatment setting
Inpatient
Outpatient
Treatment course
Index (I)
Treatment number
Maintenance (M)
Treatment number
Electrode placement
Right unilateral (d’Elia)
BT
Left ant‑right temporal
Bifrontal
Medications administered: Include
dose given
Lorazepam
mg
Atropine
mg
Caffeine
mg
Esmolol
Etomidate
Glycopyrrolate
Ketorolac
Labetalol
Methohexital
mg
NTG
Ondansetron
Propofol

Succinylcholine
Versed
Other
Seizure duration
Motor
EEG
Vital signs
Maximum HR
Maximum BP
Adverse events
None
Yes
If yes, describe
Other
Estimated blood loss
Specimen(s) removed
Comments
Changes for next ECT
Thymatron system settings/readings
Date
Time
Percentage energy set Percentage
Charge delivered
mC
Current
A

Contd...
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mg

s
s

EEG endpoint
Sec
EMG endpoint
Sec
Base HR
b/m
Peak HR
b/m
Average seizure
µV2
energy index
Stimulus duration
S
Postictal
%
suppression
index
Frequency
Hz
Maximum
µV2
sustained power
Pulse width
ms
Time to peak
Sec
power
Static impedance
Ohm
Maximum
%
sustained
coherence
Dynamic impedance Ohm
Time to peak
s
coherence
Above thymatron system settings/readings were verified for accuracy
with (name/title): _________________
Attending physician review, findings and plan
Condition at discharge from ECT recovery
ECT service
Behavior
Orientation
Vital signs
Stable for D/C
Return date
ECT: Electroconvulsive therapy, YMRS: Young Mania Rating
Scale, MADRS: Montgomery Asberg Depression Rating Scale, GDS: Geriatric
Depression Scale, MMSE: Mini‑Mental State Examination, VCUHS: Virginia
Commonwealth University Health System, CGI: Clinician Global Index, EKG:
Electrocardiogram, BT: Bitemporal, EEG: Electroencephalogram, HR: Heart rate, BP:
Blood pressure, CNS: Central nervous system, NGT: Nitroglycerin, CGS: Clinician’s
Global Scale, ROS: Review of Systems, HEENT: Head, Eyes, Ears, Nose, Throat

and changed to BF placement if the progress is deemed
insufficient. Patients with more pervasive pathologies
including mania and catatonia are initiated with BF lead
placement. Bitemporal (BT) lead placement is used if
the first eight treatments (RUL × 4, BF × 4) for MDD) or
four treatments (BF × 4 for psychosis) do not produce an
adequate response, defined as 50% reduction in MADRS
score or global improvement in psychosis/mania as judged
by the treating psychiatrist. Caffeine benzoate 250 mg is
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administered intravenously to those patients who exhibit
a limited or no seizure in the prior treatment, 5 min
before the planned electrostimulation. For postprocedure
agitation, midazolam or lorazepam is used.
Except for the psychiatrist summary, documentation of the
procedure occurs more or less contemporaneously in the
electronic hospital record (Cerner Millennium) through
conveniently located work stations. We have developed
an ECT progress and procedure form into which all data
are entered [Figure 1].
For patients with MDD, MADRS scores are recorded
before initiating treatment, before every 4th treatment and
upon the day of discharge from the ECT service. Adverse
events are documented on the ECT procedure form.
The faculty psychiatrist assesses progress in treatment,
engages with families, and liaises with the primary
treating psychiatrist throughout the ECT course and
during maintenance ECT. Medication adjustments may be
made by either the ECT psychiatrist or, when applicable,
inpatient psychiatrist with electronic communication
among the two as well as the patient and family. Typical
modifications to pharmacologic management include
withholding benzodiazepines; reducing the dosage or
withholding of lithium and tricyclics; lowering or holding
any antiseizure medication; reviewing doses of seizure
enhancing medications (bupropion, clozapine, etc.); and
administering medications to manage side effects such
as pain and migraine medications. Cardiopulmonary and
endocrine medications are not changed and are typically
to be taken as usual on days of treatment. Insulin doses
may be slightly increased during the course of ECT.
Pacemakers are interrogated after each procedure by a
cardiology technician. Anesthesiologists are responsible
for airway and cardiovascular management until the
patient successfully recovers from procedure.
Postprocedure, the patient is moved to a recovery area
within the ECT suite with a registered nurse for 15–20 min
during which there is continuous monitoring of vital
signs, oxygenation, and orientation. Subsequently, the
patient is moved to a room on the ECT unit and family
members are invited to visit with the patient while the
nurse continues checking vital signs, orientation, any
complaints every 10–15 min for about 1 h. Patients who
have received blood pressure lowering medications during
the procedure may be observed for an additional hour
to ensure there is no late drop in blood pressure. The
intravenous (IV) access is maintained for all patients until
released from the ECT Suite. Unless there is a specific
medical indication, IV fluids or other medications are
typically not ordered. However, in patients with catatonia
as well as psychosis or depression with malnutrition, we
do utilize the opportunity to provide hydration in the form
of 750 mL of Ringer lactate or half normal saline over 6 h.
After ensuring that the vital signs are normal, orientation is
consistently confirmed to self/time/place, and there are no
acute complaints, the patient is released in the company of
the escorting adult with the following instructions:
1. Mandatory: No driving or consuming alcohol
for the day. Rest for 4 h. May engage in routine

2.
3.
4.

in‑house activities. No working at heights or with
any type of machinery. No open flame cooking.
Next day: Mild in‑house activities, if previously
driving, then driving within neighborhood only with
an accompanying person provided no medical or
psychiatric symptoms including headache, dizziness,
confusion, disorientation, chest discomfort, increased
depression, suicidal thoughts, anxiety/panic, or
hallucinations
Return to ECT with a responsible adult at a specified
date and time
Medications: Individualized instructions
For any concerns or questions, the psychiatrist on‑call
is available 24/7.

The typical ECT schedule for the elderly patient without
any cognitive impairment unrelated to depression (e.g.,
dementia or mild cognitive impairment) or major medical
conditions (e.g., congestive heart failure or arrhythmia)
is three times weekly. For those with such comorbid
impairments, the schedule is typically two times weekly.
Very infrequently, we have utilized once a week treatment
for logistical reasons (e.g., transport or accompanying
provider schedule) or medical reasons such as a history
of confusion with duration >8 h.

MATERIAL AND METHODS
For the analyses included within this report, 59 unique
patients over 65 years of age were identified as receiving
ECT at the VCUHS Brain Stimulation Unit during the
years of 2015 and 2016. Within this group, nine patients
are described separately as they received maintenance
therapy during the study period; data for this report were
collected by review of the charts of the fifty patients by
the first author (ADS). We gathered information on age,
gender and racial distribution, number of treatments,
placement of electrodes, charge administered, as well
as subjective and objective indicators of outcome. We
reviewed each procedure note for documentation of any
adverse events. These included reported side effects by
patients and families, observations made by the treatment
team, and depression treatment scales (primarily MADRS)
administered during the course of treatment.

RESULTS
Analyses were conducted on the fifty patients who
received index or cluster treatments. Index treatment
course is typically 10–12 treatments in length provided
for a full episode of major depression or psychosis. Cluster
treatment is a shorter course of 4–6 treatments in length
and was provided for a partial relapse of symptoms, during
the maintenance phase.
The average age was 71.6 ± 5.2 years. There were
24 males and 26 females. Thirty‑three received index
and 17 received cluster treatments. The most common
psychiatric diagnosis was MDD (n = 36, 72%) followed
by bipolar disorder (n = 13, 26%) and schizoaffective
disorder (n = 1, 2.0%). The average number of treatments
received was 10.
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Overall, by report of patients and families, 42 out of
50 patients (84% of respondents) were significantly
improved. The psychiatrist determined that 48 out of
50 patients showed some degrees of improvement in
the target symptoms (96%). Using a modified 5‑point
Clinician Global Index, where −1= decline/worsening
of symptoms; 0 = no change; 1 = minimal improvement;
2 = moderate improvement; and 3 = high/substantial
improvement, psychiatrist determined average score
was 1.98 ± 0.78. Thirty‑four (68%) patients showed
moderate or higher improvement. Paired initial and
final MADRS scores were available however, for only
21 patients (42% of the sample); average initial scores
were 28.2 ± 9.5 and final scores were 14.9 ± 7.8. The
paired t‑test result suggested a significant improvement
after treatment (n = 21, t = 6.792, P < 0.001). Side
effects associated with treatment were common including
short‑term memory loss (n = 15, 30%), headache (n = 11,
22%), transient cognitive impairment (n = 7, 14%), other
central nervous system complaints (e.g., dizziness, fatigue,
and irritability; n = 3, 6%), other pain (n = 2, 4%), and
nausea (n = 2, 4%). Serious adverse events were not
seen except in one case with transient bigeminy and
sustained bradycardia requiring prolonged monitoring
and cardiology consultation (n = 1, 2%).
The nine patients receiving maintenance ECT included
five females and four males, with an average age of
72 years. Indications included MDD (n = 3), MDD with
psychosis (n = 2), bipolar depression (n = 3), and atypical
psychosis (n = 1). The number of maintenance ECT
sessions received ranged from 2 to 90 with an average of
27 treatments during the maintenance phase, typically
administered once a month. All of these patients maintained
a moderate or higher level of improvement and hence
M‑ECT is being continued. Patients were taking various
medications at the time of treatment which were managed
by their own primary psychiatrist.

DISCUSSION
Our data appear to be consistent with findings in the
literature in the sense that both subjective (82.3%)
and objective (96%, mild improvement or better and
68%, moderate or better) improvement in depressive
symptomatology appear to be on the order of the
benefit reported elsewhere in the literature. Our data
demonstrate significant overall reported improvement of
about 50% in depressive symptomatology as measured
by the MADRS during the index course. Incidence of
side effects and adverse effects was also similar to[8] or
lower than[9] reported in the literature. In the absence of
any mortality or serious adverse events, our experience
strongly argues for considering ECT in the treatment of
the elderly in the treatment sequence of TRD. Although
cognitive impairment is typically seen in 30% of the
patients (literature and our experience), this has not proven
to affect the patient’s quality of life (QOL) significantly or
resulted in lasting impairment. It should be noted that we
did not use an extensive battery of neuropsychological tests
or specific QOL scales which might have revealed more
subtle impairments.
120

The strengths of the program include a structured
organization of personnel with a physician as director (AKP)
and a team of dedicated professionals to oversee all aspects
of the program including quality, safety, regulatory and
legal, human rights, patient selection, and outcome as well
as the fiscal aspects. The thorough evaluation of referred
patients from all over the Commonwealth of Virginia
ensures verification of diagnosis and indication for ECT
and procedures for appropriate consent, education of
patient and significant other, and preparation for ECT. The
follow‑through by team members ensures compliance with
visits, management of safety, adjustment in treatment plan,
measurement of outcomes, and assistance with follow‑up
care. The thorough documentation allows for review and
ongoing quality improvement. The program has received
many accolades including a recent major donation from a
grateful patient/family for training students and staff in ECT.
There are, however, several weaknesses to the program
and the results reported here. In particular, capacity
is limited by space and staff and wait periods can be
4 weeks long in nonurgent cases. One hour observation
may not be sufficient. While fortunately there is no
documented instance of a serious adverse event during
the immediate hours after discharge, it may be prudent
to extend the observation time to 2 h. Assessment of
cognition is currently conducted by clinical judgment and
administration of the Mini–Mental Status Examination;
more sophisticated neuropsychological assessment may
reveal subtler abnormalities. There is only anecdotal
information on relapse after ECT without any formal
monitoring.
The results reported here are from a program review for
quality purposes and not a formal research study. They are
susceptible to contamination and bias from factors that are
not controlled such as concomitant therapies including
medication, counseling, and varying levels of care (family,
hospital, nursing home, etc.). Minor adverse effects such
as transient agitation, headache, muscle soreness, and
psychological complaints such as discomfort with the
oxygen mask and paralysis before complete sedation are
not strictly documented.
Numerous opportunities exist for improving our program
as well as filling the gaps in the literature. By no means
comprehensive or exhaustive, an arbitrary list of opportunities
from a programmatic and service perspective includes (i)
encouraging ECT programs to implement uniform assessment
procedures, (ii) maintain a database and contribute data to a
registry, and (iii) enhancing access to education for providers
on the efficacy and safety of ECT in the elderly. From a formal
research perspective, conducting studies on topics such as (i)
use of RUL versus BL in nondepressed elderly patients such
as those with catatonia and other psychotic disorders, mania,
and agitation associated with dementia and (ii) efficacy of
different schedule of ECT in the elderly using biweekly and
triweekly schedules.

CONCLUSIONS
The literature and our experience strongly support the
efficacy and safety of ECT in geriatric patients; however,
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there are some factors unique to this population which beg
further consideration when recommending this modality
of treatment. A few examples have been mentioned above.
Could the biological differences in brain tissue conductivity
be corrected by the use of medical interventions such
as preprocedure hydration, use of caffeine, or other
stimulants? Perhaps improvements such as this and others
mentioned in this manuscript could further improve the
efficacy of ECT. Some authors noted that neurotropic
effects of ECT may underlie its therapeutic benefit.
Combined therapy with pharmacologic intervention
along with brain stimulation was determined to be more
effective than monotherapy, and maintenance therapy
has demonstrated efficacy in limiting relapse. A variety
of disorders including bipolar depression, dementia with
severe agitation, mania, and schizophrenia may also be
responsive to ECT.
Maximization of benefit and minimization of memory
loss and other side effects through sequential RUL, then
BF, and then BT placement is consistent with the adult
population. ECT is accepted as a safe treatment modality
even for patients with implanted implantable cardioverter
defibrillators and other general medical problems after
consultation with the appropriate specialists; however,
the possibility of increased rate of falls, especially on the
day of ECT, as well as induction of arrhythmias during
and immediately after the procedure must be considered
when clearing elderly patients for ECT. Accessibility
is limited primarily not only by cost but also negative
public perception in the United States. Controversies
about capacity to consent and protection of human
rights, the inherent challenges of involuntary ECT, as
well as unfounded fears about disrupting the brain and
mind through electrical stimulation likely result in the
underutilization of ECT. Provider education is an important
tool in enhancing access and referral; psychoeducation
maximizes capacity to consent but may be difficult with
patients suffering from comorbid psychosis or dementia.
The viability of TMS as an alternative to ECT in the
geriatric population continues to be evaluated.
Through an examination of the existing literature on this
topic as well as a preliminary analysis of data gathered from
our program at VCUHS, we advocate for the appropriate
utilization of ECT when treating geriatric patients suffering
from TRD and other refractory psychotic and manic
conditions.
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